{"transactions":[{"id":4638369,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-09T01:59:10.000Z","date":"2026-10-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":57995,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of shares of common stock (\"Common Stock\") of BioLife Solutions, Inc. (the \"Registrant\") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation (\"Merger Sub 1\") with and into the Registrant (the \"First Merger\"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the \"Merger Agreement\"), by and among the Registrant, Repligen Corporation, a Delaware corporation (\"Repligen\"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the \"First Merger Effective Time\"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-418327","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1557271/000119312526418327/ownership.xml","form_type":"4"}},{"id":880788,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T22:55:49.000Z","date":"2026-02-24","kind":"grant","planned":false,"acquired":true,"shares":8170,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026"}],"balance_after":57995,"source":{"system":"sec-edgar","filing":"0001628280-26-012476","document":"wk-form4_1772146544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000162828026012476/wk-form4_1772146544.xml","form_type":"4"}},{"id":1196276,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-20T23:08:35.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":6876,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the \"2023 Plan\") and fully vests on the first anniversary of the measurement date of 01-02-2025."}],"balance_after":49825,"source":{"system":"sec-edgar","filing":"0001628280-25-014186","document":"wk-form4_1742512108.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000162828025014186/wk-form4_1742512108.xml","form_type":"4"}},{"id":1250183,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Administrative Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-24T21:11:52.000Z","date":"2025-02-20","kind":"exercise","planned":false,"acquired":false,"shares":1566,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Company common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the RSUs vested on February 20, 2025.  The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-third of the RSUs vested on February 20, 2025.  The remaining RSUs vest one-half on each of February 20, 2026 and February 20, 2027."}],"balance_after":3131,"derivative":{"underlying":"Common Stock","underlying_shares":1566},"source":{"system":"sec-edgar","filing":"0001062993-25-003344","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299325003344/form4.xml","form_type":"4"}},{"id":1250182,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Administrative Officer"}}],"security":"Common Stock","published_at":"2025-02-24T21:11:52.000Z","date":"2025-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":491,"price":103.46,"value":50798.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by Zimmer Biomet Holdings, Inc. (the \"Company\") to satisfy tax withholding obligations on the vesting of restricted stock units (\"RSUs\")."}],"balance_after":11906,"source":{"system":"sec-edgar","filing":"0001062993-25-003344","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299325003344/form4.xml","form_type":"4"}},{"id":1250181,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Administrative Officer"}}],"security":"Common Stock","published_at":"2025-02-24T21:11:52.000Z","date":"2025-02-20","kind":"exercise","planned":false,"acquired":true,"shares":1566,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12397,"source":{"system":"sec-edgar","filing":"0001062993-25-003344","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299325003344/form4.xml","form_type":"4"}},{"id":1260961,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Administrative Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-19T22:56:51.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":false,"shares":5572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of Company common stock."}],"balance_after":0,"derivative":{"exercise_date":"2025-02-18","expiration_date":"2025-02-18","underlying":"Common Stock","underlying_shares":5572},"source":{"system":"sec-edgar","filing":"0001062993-25-002910","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299325002910/form4.xml","form_type":"4"}},{"id":1260960,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Administrative Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-19T22:56:51.000Z","date":"2025-02-14","kind":"grant","planned":false,"acquired":true,"shares":5572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of Company common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"On February 18, 2022, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2022 - 2024.  As determined on February 14, 2025, based on actual performance, the reporting person earned 5,572 RSUs, which vested on February 18, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"On February 18, 2022, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2022 - 2024.  As determined on February 14, 2025, based on actual performance, the reporting person earned 5,572 RSUs, which vested on February 18, 2025."}],"balance_after":5572,"derivative":{"exercise_date":"2025-02-18","expiration_date":"2025-02-18","underlying":"Common Stock","underlying_shares":5572},"source":{"system":"sec-edgar","filing":"0001062993-25-002910","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299325002910/form4.xml","form_type":"4"}},{"id":1260959,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Administrative Officer"}}],"security":"Common Stock","published_at":"2025-02-19T22:56:51.000Z","date":"2025-02-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":1792,"price":101,"value":180992.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by Zimmer Biomet Holdings, Inc. (the \"Company\") to satisfy tax withholding obligations on the vesting of restricted stock units (\"RSUs\")."}],"balance_after":10831,"source":{"system":"sec-edgar","filing":"0001062993-25-002910","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299325002910/form4.xml","form_type":"4"}},{"id":1260958,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Administrative Officer"}}],"security":"Common Stock","published_at":"2025-02-19T22:56:51.000Z","date":"2025-02-18","kind":"exercise","planned":false,"acquired":true,"shares":5572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 205 shares acquired under the Employee Stock Purchase Plan through February 18, 2025."}],"balance_after":12623,"source":{"system":"sec-edgar","filing":"0001062993-25-002910","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299325002910/form4.xml","form_type":"4"}},{"id":1582781,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-13T01:44:56.000Z","date":"2024-03-08","kind":"grant","planned":false,"acquired":true,"shares":11264,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the \"2023 Plan\") and fully vests on the first anniversary of the grant date."}],"balance_after":42949,"source":{"system":"sec-edgar","filing":"0001628280-24-010751","document":"wk-form4_1710294284.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000162828024010751/wk-form4_1710294284.xml","form_type":"4"}},{"id":1587331,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2024-03-08T22:03:41.000Z","date":"2024-03-06","kind":"exercise","planned":false,"acquired":false,"shares":1419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the RSUs vested on March 6, 2024.  The remaining RSUs vest one-half on each of March 6, 2025 and March 6, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-third of the RSUs vested on March 6, 2024.  The remaining RSUs vest one-half on each of March 6, 2025 and March 6, 2026."}],"balance_after":2837,"derivative":{"underlying":"Common Stock","underlying_shares":1419},"source":{"system":"sec-edgar","filing":"0001062993-24-006022","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299324006022/form4.xml","form_type":"4"}},{"id":1587330,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-03-08T22:03:41.000Z","date":"2024-03-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":445,"price":125.82,"value":55989.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of restricted stock units (\"RSUs\")."}],"balance_after":6846,"source":{"system":"sec-edgar","filing":"0001062993-24-006022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299324006022/form4.xml","form_type":"4"}},{"id":1587329,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-03-08T22:03:41.000Z","date":"2024-03-06","kind":"exercise","planned":false,"acquired":true,"shares":1419,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7291,"source":{"system":"sec-edgar","filing":"0001062993-24-006022","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299324006022/form4.xml","form_type":"4"}},{"id":1616511,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-28T01:57:03.000Z","date":"2024-02-25","kind":"exercise","planned":false,"acquired":false,"shares":1762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Company common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"This number of restricted stock units (\"RSUs\") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the \"Company\") spinoff of Zimvie Inc. In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs."}],"balance_after":0,"derivative":{"exercise_date":"2024-02-25","expiration_date":"2024-02-25","underlying":"Common Stock","underlying_shares":1762},"source":{"system":"sec-edgar","filing":"0001062993-24-004687","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299324004687/form4.xml","form_type":"4"}},{"id":1616510,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-02-28T01:57:03.000Z","date":"2024-02-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":588,"price":128.8,"value":75734.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of RSUs."}],"balance_after":5872,"source":{"system":"sec-edgar","filing":"0001062993-24-004687","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299324004687/form4.xml","form_type":"4"}},{"id":1616509,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-02-28T01:57:03.000Z","date":"2024-02-25","kind":"exercise","planned":false,"acquired":true,"shares":1762,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number of restricted stock units (\"RSUs\") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the \"Company\") spinoff of Zimvie Inc. In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 195 shares acquired under the Company's Employee Stock Purchase Plan through February 1, 2024."}],"balance_after":6460,"source":{"system":"sec-edgar","filing":"0001062993-24-004687","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299324004687/form4.xml","form_type":"4"}},{"id":1625911,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-23T01:59:26.000Z","date":"2024-02-20","kind":"grant","planned":false,"acquired":true,"shares":4697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests annually over three years in increments of one-third each year, commencing February 20, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Vests annually over three years in increments of one-third each year, commencing February 20, 2025."}],"balance_after":4697,"derivative":{"underlying":"Common Stock","underlying_shares":4697},"source":{"system":"sec-edgar","filing":"0001062993-24-004132","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299324004132/form4.xml","form_type":"4"}},{"id":1750704,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-03T21:10:12.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":495,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant."}],"balance_after":31685,"source":{"system":"sec-edgar","filing":"0001628280-23-036780","document":"wk-form4_1699045799.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000162828023036780/wk-form4_1699045799.xml","form_type":"4"}},{"id":1763052,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-10T21:26:53.000Z","date":"2023-10-01","kind":"grant","planned":false,"acquired":true,"shares":362,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant."}],"balance_after":31190,"source":{"system":"sec-edgar","filing":"0001628280-23-034206","document":"wk-form4_1696973203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000162828023034206/wk-form4_1696973203.xml","form_type":"4"}},{"id":1963792,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2023-03-08T21:25:17.000Z","date":"2023-03-06","kind":"grant","acquired":true,"shares":4256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests annually over three years in increments of one-third each year, commencing March 6, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Vests annually over three years in increments of one-third each year, commencing March 6, 2024."}],"balance_after":4256,"derivative":{"underlying":"Common Stock","underlying_shares":4256},"source":{"system":"sec-edgar","filing":"0001062993-23-006280","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299323006280/form4.xml","form_type":"4"}},{"id":1996373,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-23T22:52:01.000Z","date":"2023-02-21","kind":"exercise","acquired":false,"shares":1046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of Company common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"This number of restricted stock units (\"RSUs\") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the \"Company\") spinoff of Zimvie Inc.  In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs."}],"balance_after":0,"derivative":{"exercise_date":"2023-02-21","expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":1046},"source":{"system":"sec-edgar","filing":"0001062993-23-004623","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299323004623/form4.xml","form_type":"4"}},{"id":1996372,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2023-02-23T22:52:01.000Z","date":"2023-02-21","kind":"tax_withholding","acquired":false,"shares":361,"price":124.73,"value":45027.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld by the Company to satisfy tax withholding obligations on the vesting of RSUs."}],"balance_after":4503,"source":{"system":"sec-edgar","filing":"0001062993-23-004623","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299323004623/form4.xml","form_type":"4"}},{"id":1996371,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2023-02-23T22:52:01.000Z","date":"2023-02-21","kind":"exercise","acquired":true,"shares":1046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This number of restricted stock units (\"RSUs\") reflects the adjustments that occurred as of March 1, 2022 in connection with Zimmer Biomet Holdings, Inc.'s (the \"Company\") spinoff of Zimvie Inc.  In connection with the spinoff, each RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit, which adjustments were made following the initial reporting of these RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 194 shares acquired under the Company's Employee Stock Purchase Plan on June 30, 2022."}],"balance_after":4864,"source":{"system":"sec-edgar","filing":"0001062993-23-004623","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299323004623/form4.xml","form_type":"4"}},{"id":2053324,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-01-19T00:00:15.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":10187,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the \"Plan\") and fully vests on the first anniversary of the grant date."}],"balance_after":30828,"source":{"system":"sec-edgar","filing":"0001437749-23-001264","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000143774923001264/rdgdoc.xml","form_type":"4"}},{"id":2198313,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-08-03T00:00:57.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":259,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant."}],"balance_after":20641,"source":{"system":"sec-edgar","filing":"0001437749-22-018511","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000143774922018511/rdgdoc.xml","form_type":"4"}},{"id":2213262,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-07T00:01:34.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":341,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant."}],"balance_after":20382,"source":{"system":"sec-edgar","filing":"0001437749-22-016765","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000143774922016765/rdgdoc.xml","form_type":"4"}},{"id":2246151,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-04T00:01:41.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":311,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant."}],"balance_after":20041,"source":{"system":"sec-edgar","filing":"0001437749-22-014307","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000143774922014307/rdgdoc.xml","form_type":"4"}},{"id":2276774,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-11T00:01:20.000Z","date":"2022-05-06","kind":"grant","acquired":true,"shares":14730,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the \"Plan\") and fully vests on the first anniversary of the grant date."}],"balance_after":19730,"source":{"system":"sec-edgar","filing":"0001437749-22-011803","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000143774922011803/rdgdoc.xml","form_type":"4"}},{"id":2284699,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2022-05-03T20:41:12.000Z","date":"2022-05-01","kind":"exercise","acquired":false,"shares":531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Amount reflects the adjustments that occurred as of March 1, 2022 in connection with the Company's spinoff of ZimVie Inc. In connection with the spinoff, each outstanding RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The remaining 531 RSUs vested on May 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The remaining 531 RSUs vested on May 1, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Amount reflects the adjustments that occurred as of March 1, 2022 in connection with the Company's spinoff of ZimVie Inc. In connection with the spinoff, each outstanding RSU was adjusted to preserve the intrinsic value of such award by multiplying it by an equity exchange ratio, rounded up to the nearest whole unit."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":531},"source":{"system":"sec-edgar","filing":"0001062993-22-011409","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299322011409/form4.xml","form_type":"4"}},{"id":2284698,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2022-05-03T20:41:12.000Z","date":"2022-05-01","kind":"tax_withholding","acquired":false,"shares":167,"price":122.43,"value":20445.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by Zimmer Biomet Holdings, Inc. (the \"Company\") to satisfy tax withholding obligations on the vesting of restricted stock units (\"RSUs\")."}],"balance_after":3624,"source":{"system":"sec-edgar","filing":"0001062993-22-011409","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299322011409/form4.xml","form_type":"4"}},{"id":2284697,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2022-05-03T20:41:12.000Z","date":"2022-05-01","kind":"exercise","acquired":true,"shares":531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 162 shares acquired under the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan on June 30, 2021 and December 31, 2021."}],"balance_after":3791,"source":{"system":"sec-edgar","filing":"0001062993-22-011409","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299322011409/form4.xml","form_type":"4"}},{"id":2355729,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-03T21:06:04.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":1708,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units (\"PRSUs\") held by Company employees, included the reporting person, were converted into time-based RSUs.  Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level.  The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units (\"PRSUs\") held by Company employees, included the reporting person, were converted into time-based RSUs.  Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level.  The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units (\"PRSUs\") held by Company employees, included the reporting person, were converted into time-based RSUs.  Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level.  The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed."}],"balance_after":1708,"derivative":{"exercise_date":"2024-02-25","expiration_date":"2024-02-25","underlying":"Common Stock","underlying_shares":1708},"source":{"system":"sec-edgar","filing":"0001062993-22-006629","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299322006629/form4.xml","form_type":"4"}},{"id":2355728,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-03T21:06:04.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":1014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units (\"PRSUs\") held by Company employees, included the reporting person, were converted into time-based RSUs.  Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level.  The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units (\"PRSUs\") held by Company employees, included the reporting person, were converted into time-based RSUs.  Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level.  The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with the Company's spinoff of ZimVie Inc., certain performance-based restricted stock units (\"PRSUs\") held by Company employees, included the reporting person, were converted into time-based RSUs.  Effective as of March 1, 2022, PRSU awards granted in 2020 were converted into RSUs at a 50% payout level and PRSU awards granted in 2021 were converted into RSUs at an 82.5% payout level.  The vesting date of these awards remains the same, with the RSUs converted from 2020 PRSUs and 2021 PRSUs scheduled to vest on February 21, 2023 and February 25, 2024, respectively. Further, in connection with the spinoff, the RSUs will be adjusted pursuant to an exchange ratio, in order to preserve the intrinsic value of the original award. The RSUs reported on this Form 4 reflect the number of RSUs following conversion from PRSUs, but do not reflect the exchange ratio adjustment, as such calculations have not yet been completed."}],"balance_after":1014,"derivative":{"exercise_date":"2023-02-21","expiration_date":"2023-02-21","underlying":"Common Stock","underlying_shares":1014},"source":{"system":"sec-edgar","filing":"0001062993-22-006629","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299322006629/form4.xml","form_type":"4"}},{"id":2379192,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-23T22:05:07.000Z","date":"2022-02-18","kind":"grant","acquired":true,"shares":12891,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests annually over three years in increments of one-third each year, commencing on February 18, 2023."}],"balance_after":12891,"derivative":{"exercise_price":120.82,"expiration_date":"2032-02-18","underlying":"Common Stock","underlying_shares":12891},"source":{"system":"sec-edgar","filing":"0001062993-22-005364","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299322005364/form4.xml","form_type":"4"}},{"id":2733230,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2021-05-03T20:41:28.000Z","date":"2021-05-01","kind":"exercise","acquired":false,"shares":515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"515 of the RSUs vested on May 1, 2021.  The remaining 515 RSUs will vest on May 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"515 of the RSUs vested on May 1, 2021.  The remaining 515 RSUs will vest on May 1, 2022."}],"balance_after":515,"derivative":{"underlying":"Common Stock","underlying_shares":515},"source":{"system":"sec-edgar","filing":"0001062993-21-004047","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321004047/form4.xml","form_type":"4"}},{"id":2733229,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2021-05-03T20:41:28.000Z","date":"2021-05-01","kind":"tax_withholding","acquired":false,"shares":162,"price":177.27,"value":28717.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by Zimmer Biomet Holdings, Inc. (the \"Company\") to satisfy tax withholding obligations on the vesting of restricted stock units (\"RSUs\")."}],"balance_after":3098,"source":{"system":"sec-edgar","filing":"0001062993-21-004047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321004047/form4.xml","form_type":"4"}},{"id":2733228,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2021-05-03T20:41:28.000Z","date":"2021-05-01","kind":"exercise","acquired":true,"shares":515,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3260,"source":{"system":"sec-edgar","filing":"0001062993-21-004047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321004047/form4.xml","form_type":"4"}},{"id":2749883,"issuer":{"id":4614,"kind":"organization","name":"BIOLIFE SOLUTIONS INC","symbol":"BLFS"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-04-15T01:36:32.000Z","date":"2021-04-12","kind":"grant","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock award was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and fully vests on the first anniversary of the grant date."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001437749-21-008947","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/834365/000143774921008947/rdgdoc.xml","form_type":"4"}},{"id":2821248,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Restricted Stock Units","published_at":"2021-03-02T23:35:46.000Z","date":"2021-02-26","kind":"exercise","acquired":false,"shares":156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Earned RSUs vested on February 26, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Earned RSUs vested on February 26, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":156},"source":{"system":"sec-edgar","filing":"0001062993-21-002183","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321002183/form4.xml","form_type":"4"}},{"id":2821247,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2021-03-02T23:35:46.000Z","date":"2021-02-26","kind":"tax_withholding","acquired":false,"shares":58,"price":163.92,"value":9507.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by Zimmer Biomet Holdings, Inc. (the \"Company\") to satisfy tax withholding obligations on the vesting of restricted stock units (\"RSUs\")."}],"balance_after":2745,"source":{"system":"sec-edgar","filing":"0001062993-21-002183","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321002183/form4.xml","form_type":"4"}},{"id":2821246,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2021-03-02T23:35:46.000Z","date":"2021-02-26","kind":"exercise","acquired":true,"shares":156,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2803,"source":{"system":"sec-edgar","filing":"0001062993-21-002183","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321002183/form4.xml","form_type":"4"}},{"id":2827039,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Strategy Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-01T21:53:12.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":8479,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests annually over four years in increments of 25% each year, commencing on February 25, 2022."}],"balance_after":8479,"derivative":{"exercise_price":163.79,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":8479},"source":{"system":"sec-edgar","filing":"0001062993-21-002090","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321002090/form4.xml","form_type":"4"}},{"id":2843631,"issuer":{"id":3278,"kind":"organization","name":"ZIMMER BIOMET HOLDINGS, INC.","symbol":"ZBH"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & CSO"}}],"security":"Restricted Stock Units","published_at":"2021-02-22T22:04:49.000Z","date":"2021-02-18","kind":"grant","acquired":true,"shares":156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 156 RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Earned RSUs will vest on February 26, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Earned RSUs will vest on February 26, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 156 RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 26, 2019, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2019 - 2021, with an opportunity for interim payouts after 2019 and 2020 depending on actual performance. As determined on February 18, 2021, based on actual performance for 2020, the reporting person earned 156 RSUs."}],"balance_after":156,"derivative":{"underlying":"Common Stock","underlying_shares":156},"source":{"system":"sec-edgar","filing":"0001062993-21-001858","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1136869/000106299321001858/form4.xml","form_type":"4"}},{"id":4497320,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Restricted Stock Units","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":2028,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2028},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497319,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Stock Options (Right to Buy)","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":25464,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table.  Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2).  The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table.  Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2).  The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":61.62,"exercise_date":"2016-12-17","expiration_date":"2023-12-07","underlying":"Common Stock","underlying_shares":25464},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497318,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Restricted Stock Units","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":1114,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table.  Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2).  The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1114},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497317,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Stock Options (Right to Buy)","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":19616,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table.  Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2).  The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table.  Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2).  The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":69.08,"exercise_date":"2015-12-17","expiration_date":"2022-12-08","underlying":"Common Stock","underlying_shares":19616},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497316,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Restricted Stock Units","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":401,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each unvested restricted stock unit was assumed by Abbott and converted into restricted stock units for the number of shares of Abbott Common Stock equal to the product (rounded to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such restricted stock unit immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":401},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497315,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Stock Options (Right to Buy)","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":13380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table.  Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2).  The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each option provided for vesting in four equal installments on December 17 commencing on the date shown in the table.  Pursuant to the Merger Agreement, the vested options were treated as set forth in note (2).  The unvested options were assumed by Abbott and converted into an option to acquire the number of shares of Abbott Common Stock equal to the product (rounded down to the nearest whole share) of (i) the number of shares of Issuer Common Stock subject to such option immediately prior to the Mergers multiplied by (ii) the Stock Award Exchange Ratio (as defined in the Merger Agreement), at an exercise price per share of Abbott stock equal to the quotient (rounded up to the nearest whole cent) of (A) the per share exercise price for the shares of Issuer Common Stock subject to such option immediately prior to the Mergers divided by (B) the Stock Award Exchange Ratio."}],"balance_after":0,"derivative":{"exercise_price":59.41,"exercise_date":"2014-12-17","expiration_date":"2021-12-10","underlying":"Common Stock","underlying_shares":13380},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497314,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Stock Options (Right to Buy)","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":14749,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock (\"Net Exercise Shares\") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock (\"Net Exercise Shares\") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":35.27,"exercise_date":"2013-12-17","expiration_date":"2020-12-10","underlying":"Common Stock","underlying_shares":14749},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497313,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Stock Options (Right to Buy)","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":1383,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock (\"Net Exercise Shares\") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, each option that was fully vested and exercisable immediately prior to the Mergers was deemed exercised pursuant to a cashless exercise and settled by issuance of a number of shares of Issuer Common Stock (\"Net Exercise Shares\") equal to the excess (rounded down to the nearest whole share, but with any partial shares otherwise issuable settled in cash) of (i) the number of Issuer shares of Common Stock subject to such option immediately prior to the Mergers over (ii) the number of whole and partial (computed to the nearest four decimal places) Issuer shares of Common Stock that, when multiplied by the Company equity plan-defined FMV, is equal to the aggregate exercise price of the exercised options. Each Net Exercise Share was then canceled and converted into the right to receive the Merger Consideration, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":34.96,"exercise_date":"2012-12-17","expiration_date":"2019-12-12","underlying":"Common Stock","underlying_shares":1383},"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4497312,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2017-01-06T13:13:30.000Z","date":"2017-01-04","kind":"disposition_to_issuer","acquired":false,"shares":8732,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2016, by and among Abbott Laboratories (\"Abbott\"), the Issuer, Vault Merger Sub, Inc. and Vault Merger Sub, LLC (the \"Merger Agreement\"), each share of Issuer Common Stock was cancelled in exchange for $46.75 in cash and 0.8708 of a share of Abbott Common Stock (the \"Merger Consideration\"), less any applicable withholding taxes, and provided that cash is payable in respect of any fractional shares of Abbott stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-17-000588","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911017000588/edgar.xml","form_type":"4"}},{"id":4516250,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Restricted Stock Units","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":false,"shares":676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest 25% on December 17th annually beginning the date shown."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":2028,"derivative":{"exercise_date":"2016-12-17","underlying":"Common Stock","underlying_shares":2704},"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516249,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Restricted Stock Units","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":false,"shares":557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest 25% on December 17th annually beginning the date shown."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":1114,"derivative":{"exercise_date":"2015-12-17","underlying":"Common Stock","underlying_shares":1671},"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516248,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Restricted Stock Units","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":false,"shares":401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest 25% on December 17th annually beginning the date shown."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":401,"derivative":{"exercise_date":"2014-12-17","underlying":"Common Stock","underlying_shares":802},"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516247,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Restricted Stock Units","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":false,"shares":698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units will vest 25% on December 17th annually beginning the date shown."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":0,"derivative":{"exercise_date":"2013-12-17","underlying":"Common Stock","underlying_shares":698},"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516246,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"tax_withholding","acquired":false,"shares":228,"price":79.2,"value":18057.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"676 shares of restricted stock vested on December 17, 2016. 228 shares were used to pay taxes and 448 shares were released."}],"balance_after":8732,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516245,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":true,"shares":676,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":8960,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516244,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"tax_withholding","acquired":false,"shares":188,"price":79.2,"value":14889.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"557 shares of restricted stock vested on December 17, 2016. 188 shares were used to pay taxes and 369 shares were released."}],"balance_after":8284,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516243,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":true,"shares":557,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":8472,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516242,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"tax_withholding","acquired":false,"shares":135,"price":79.2,"value":10692.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"401 shares of restricted stock vested on December 17, 2016. 135 shares were used to pay taxes and 266 shares were released."}],"balance_after":7915,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516241,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":true,"shares":401,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":8050,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516240,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"tax_withholding","acquired":false,"shares":235,"price":79.2,"value":18612.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"698 shares of restricted stock vested on December 17, 2016. 235 shares were used to pay taxes and 463 shares were released."}],"balance_after":7649,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}},{"id":4516239,"issuer":{"id":179857,"kind":"organization","name":"ST JUDE MEDICAL, LLC","symbol":"STJ"},"owners":[{"id":64609,"kind":"person","name":"Ellingson Rachel","position":1,"cik":"0001557271","reported_name":"Ellingson Rachel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Global Communications"}}],"security":"Common Stock","published_at":"2016-12-20T16:58:28.000Z","date":"2016-12-17","kind":"exercise","acquired":true,"shares":698,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."}],"balance_after":7884,"source":{"system":"sec-edgar","filing":"0001179110-16-033307","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/203077/000117911016033307/edgar.xml","form_type":"4"}}]}